{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:52:17Z","timestamp":1770742337163,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","award":["DES-156672"],"award-info":[{"award-number":["DES-156672"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2025.100821","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:16:10Z","timestamp":1759346170000},"page":"100821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar Anti\u2013tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-world Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods\/CIRC Registry"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3201-4522","authenticated-orcid":false,"given":"Banke","family":"Oketola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasha","family":"Bernatsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luck","family":"Lukusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano S.","family":"Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Autumn","family":"Neville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvette","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Narula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waqqas","family":"Afif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina G.","family":"Birck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros","family":"Zezos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gastha.2025.100821_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14309\/ajg.0000000000000844","article-title":"Biosimilars in inflammatory bowel disease","volume":"116","author":"Buchner","year":"2021","journal-title":"Off J Am Coll Gastroenterol ACG"},{"issue":"6","key":"10.1016\/j.gastha.2025.100821_bib2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14712598.2018.1469620","article-title":"Progress with infliximab biosimilars for inflammatory bowel disease","volume":"18","author":"Kurti","year":"2018","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"10.1016\/j.gastha.2025.100821_bib3","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.gastha.2025.100821_bib4","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/apt.13990","article-title":"Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-\u03b1 agent (infliximab), in inflammatory bowel diseases","volume":"45","author":"Komaki","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"sup1","key":"10.1016\/j.gastha.2025.100821_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1586\/17474124.2015.1091309","article-title":"Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea","volume":"9","author":"Park","year":"2015","journal-title":"Expet Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.gastha.2025.100821_bib6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40264-018-0684-9","article-title":"Safety of biologics, including biosimilars: perspectives on current status and future direction","volume":"41","author":"Ingrasciotta","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.gastha.2025.100821_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/429031","article-title":"The role of physical exercise in inflammatory bowel disease","volume":"2014","author":"Bilski","year":"2014","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1016\/j.gastha.2025.100821_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/SGA.0000000000000395","article-title":"Disease-related worries in persons with crohn disease: an interview study","volume":"42","author":"Wahlin","year":"2019","journal-title":"Gastroenterol Nurs"},{"issue":"2","key":"10.1016\/j.gastha.2025.100821_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2036.2010.04347.x","article-title":"Systematic review: fatigue in inflammatory bowel disease","volume":"32","author":"van Langenberg","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.gastha.2025.100821_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00384-020-03727-3","article-title":"Abdominal pain in quiescent inflammatory bowel disease","volume":"36","author":"Coates","year":"2021","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.gastha.2025.100821_bib11","series-title":"Inflammatory bowel disease: the facts","author":"Langmead","year":"2008"},{"issue":"2","key":"10.1016\/j.gastha.2025.100821_bib12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/ecco-jcc\/jjv195","article-title":"Classifying back pain and peripheral joint complaints in inflammatory bowel disease patients: a prospective longitudinal follow-up study","volume":"10","author":"Van Erp","year":"2016","journal-title":"J Crohn's Colitis"},{"issue":"4","key":"10.1016\/j.gastha.2025.100821_bib13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41575-018-0091-9","article-title":"Fatigue in IBD: epidemiology, pathophysiology and management","volume":"16","author":"Borren","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.gastha.2025.100821_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/apt.13870","article-title":"The contribution of clinical and psychosocial factors to fatigue in 182 patients with inflammatory bowel disease: a cross-sectional study","volume":"45","author":"Artom","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.gastha.2025.100821_bib15","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10620-020-06222-5","article-title":"Improvement of fatigue and quality of life in patients with quiescent inflammatory bowel disease following a personalized exercise program","volume":"66","author":"van Erp","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"1-2","key":"10.1016\/j.gastha.2025.100821_bib16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000442929","article-title":"Psychological stress and depression: risk factors for IBD?","volume":"34","author":"Bernstein","year":"2016","journal-title":"Dig Dis"},{"issue":"6","key":"10.1016\/j.gastha.2025.100821_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156666","article-title":"Pain in IBD patients: very frequent and frequently insufficiently taken into account","volume":"11","author":"Zeitz","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.gastha.2025.100821_bib18","first-page":"1571","article-title":"The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease","volume":"91","author":"Irvine","year":"1996","journal-title":"Am J Gastroenterol (Springer Nature)"},{"key":"10.1016\/j.gastha.2025.100821_bib19","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1016\/j.gastha.2025.100821_bib20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.gastha.2025.100821_bib21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000503859","article-title":"Persistence with biologic treatment in patients with inflammatory bowel disease: a German claims data analysis","volume":"102","author":"Mevius","year":"2021","journal-title":"Digestion"},{"issue":"6","key":"10.1016\/j.gastha.2025.100821_bib22","first-page":"1284","article-title":"Trends in corticosteroid use during the era of biologic therapy: a population-based analysis","volume":"116","author":"Targownik","year":"2021","journal-title":"Off JAm Coll Gastroenterol ACG"},{"issue":"6","key":"10.1016\/j.gastha.2025.100821_bib23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/jcag\/gwac021","article-title":"Declining corticosteroid use for inflammatory bowel disease across Alberta: a population-based cohort study","volume":"5","author":"Seow","year":"2022","journal-title":"J Can Assoc Gastroenterol"},{"issue":"2","key":"10.1016\/j.gastha.2025.100821_bib24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5009\/gnl19433","article-title":"Comparison of long-term outcomes of infliximab versus adalimumab treatment in biologic-na\u00efve patients with ulcerative colitis","volume":"15","author":"Lee","year":"2021","journal-title":"Gut Liver"},{"issue":"5","key":"10.1016\/j.gastha.2025.100821_bib25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/MEG.0000000000002087","article-title":"Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients","volume":"33","author":"Tursi","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.gastha.2025.100821_bib26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/apt.16361","article-title":"Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study","volume":"53","author":"Casanova","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2025.100821_bib27","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11096-020-00978-6","article-title":"Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease","volume":"42","author":"Gil-Candel","year":"2020","journal-title":"Int J Clin Pharm"},{"issue":"Suppl 1","key":"10.1016\/j.gastha.2025.100821_bib28","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/jcag\/gwy054","article-title":"The impact of inflammatory bowel disease in Canada 2018: epidemiology","volume":"2","author":"Kaplan","year":"2019","journal-title":"J Can Assoc Gastroenterol"},{"issue":"11","key":"10.1016\/j.gastha.2025.100821_bib29","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1155\/2012\/984575","article-title":"Inflammatory bowel disease: a Canadian burden of illness review","volume":"26","author":"Rocchi","year":"2012","journal-title":"Can J Gastroenterol"},{"issue":"6","key":"10.1016\/j.gastha.2025.100821_bib30","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2025.100821_bib31","series-title":"Chronic abdominal pain in IBD research initiative: unraveling biological mechanisms and patient heterogeneity to personalize treatment and improve clinical outcomes","first-page":"otab034","author":"Hurtado-Lorenzo","year":"2021"},{"issue":"4","key":"10.1016\/j.gastha.2025.100821_bib32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000496054","article-title":"Detailed multi-dimensional assessment of fatigue in inflammatory bowel disease","volume":"3","author":"Aluzaite","year":"2019","journal-title":"Inflamm Intestinal Dis"},{"issue":"3","key":"10.1016\/j.gastha.2025.100821_bib33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/00365521.2016.1256425","article-title":"Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: the IBSEN study","volume":"52","author":"Huppertz-Hauss","year":"2017","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.gastha.2025.100821_bib34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/ecco-jcc\/jjz148","article-title":"Longitudinal trajectory of fatigue with initiation of biologic therapy in inflammatory bowel diseases: a prospective cohort study","volume":"14","author":"Borren","year":"2020","journal-title":"J Crohn's Colitis"},{"issue":"5","key":"10.1016\/j.gastha.2025.100821_bib35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S2468-1253(21)00014-5","article-title":"Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"6","author":"Barberio","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.gastha.2025.100821_bib36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ecco-jcc\/jju025","article-title":"Back\/Joint pain, illness perceptions and coping are important predictors of quality of life and work productivity in patients with inflammatory bowel disease: a 12-month longitudinal study","volume":"9","author":"van der Have","year":"2015","journal-title":"J Crohn's Colitis"},{"issue":"2","key":"10.1016\/j.gastha.2025.100821_bib37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/gutjnl-2019-318440","article-title":"Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study","volume":"69","author":"Murthy","year":"2020","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.gastha.2025.100821_bib38","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.cgh.2022.02.021","article-title":"Earlier anti-TNF initiation leads to long-term lower health care utilization in Crohn's disease but not in ulcerative colitis","volume":"20","author":"Targownik","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.gastha.2025.100821_bib39","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/ibd\/izaa166","article-title":"No change in surgical and hospitalization trends despite higher exposure to anti-tumor necrosis factor in inflammatory bowel disease in the Qu\u00e9bec provincial database from 1996 to 2015","volume":"27","author":"Verdon","year":"2021","journal-title":"Inflamm Bowel Dis"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572325002080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572325002080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T01:12:42Z","timestamp":1770685962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572325002080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2772572325002080"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2025.100821","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar Anti\u2013tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-world Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods\/CIRC Registry","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2025.100821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}],"article-number":"100821"}}